London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.
General Anesthesia Drugs MarketThe global general anesthesia drugs market, valued at USD 4,978.1 million in 2023, is poised for steady growth, with projections indicating a compound annual growth rate ...
and Hikma and partner Vectura require a further trial to get their drug past the FDA. A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early ...
Tobacco giant Philip Morris International (PMI) has doubled down on its move into the pharmaceutical sector ... says matches up with its focus on inhalation and aerosolisation devices.
Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...
Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...
Hikma Pharmaceuticals Usa Inc was founded in 2011 and operates in Eatontown, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC ...
The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback